Chronic Myeloid Leukemia News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Treatment-free remission of chronic myeloid leukemia is possible following second-line nilotinib - Medical Xpress



Medical Xpress
 
Treatment-free remission of chronic myeloid leukemia is possible following second-line nilotinib 
Medical Xpress
Treatment-free remission seems to be achievable in patients with chronic myeloid leukemia (CML) who have achieved sustained deep molecular response (DMR) after discontinuation of second-line nilotinib therapy. Results from a Phase 2, open-label study ...
Treatment-free remission of chronic myeloid leukemia possible after second-line nilotinib 2 Minute Medicine
Treatment-free remission of chronic myeloid leukemia achievable ... Healio
Treatment-Free Remission After Second-Line Nilotinib: ENESTop ... Annals of Internal Medicine

all 5 news articles » 


Second-Line Nilotinib May Enable Patients With CML to Achieve ... - AJMC.com Managed Markets Network



Mirage News
 
Second-Line Nilotinib May Enable Patients With CML to Achieve ... 
AJMC.com Managed Markets Network
Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response can maintain treatment-free remission for at least 48 weeks after using second-line nilotinib, according to a new study published in Annals of Internal Medicine.
Treatment-Free Remission of CML Feasible for Some After Second ... Journal of Clinical Pathways

all 3 news articles » 


Chronic Myeloid Leukemia Advisor - Cancer Therapy Advisor



Journal of Clinical Pathways
 
Chronic Myeloid Leukemia Advisor 
Cancer Therapy Advisor
The BCR-ABL tyrosine kinase inhibitors (TKIs) were an early example of a successful targeted cancer treatment and have dramatically improved outcomes for patients diagnosed with chronic myeloid leukemia (CML) ? and advances in TKI treatment continue ...
NCCN Updates Chronic Myeloid Leukemia Guidelines Journal of Clinical Pathways

all 2 news articles » 


Chronic myeloid Leukemia Pipeline Highlights - 2017 Update + Forecasts to 2020 - ResearchAndMarkets.com - Business Wire (press release)



Chronic myeloid Leukemia Pipeline Highlights - 2017 Update + Forecasts to 2020 - ResearchAndMarkets.com 
Business Wire (press release)
Chronic myeloid Leukemia Pipeline Highlights - 2017 Update, provides the most up-to-date information on key pipeline products in the global Chronic myeloid Leukemia market. It covers emerging therapies for Chronic myeloid Leukemia in active clinical ...

and more » 


Undervalued And Attractive: Pick Up Novartis In 2018 - Seeking Alpha



Undervalued And Attractive: Pick Up Novartis In 2018 
Seeking Alpha
And this regimen has also received FDA breakthrough therapy status for stage III melanoma which is BRAF V600 mutation positive and also completely resected. Tasigna has also been witnessing robust demand trends in the pediatric treatment-na´ve ...

 


Chronic Myeloid Leukemia (CML) Tretament Market to Register Strong Expansion and Growth by 2025- Acute Market ... - Industry Today (press release)



Chronic Myeloid Leukemia (CML) Tretament Market to Register Strong Expansion and Growth by 2025- Acute Market ... 
Industry Today (press release)
Because they are not fully mature, they are unable to work properly to fight infections leading to a shortage of red cells and platelets that can cause anemia, bleeding and/or bruising. The global prevalence of CML is estimated to be about 70,000 in ...
Chronic Myelocytic Leukemia H2 : New Development in Drug ... NewsMaker (press release)
Chronic Myelogenous Leukemia Treatment Market Analysis, Trends ... MilTech

all 3 news articles » 


Chronic Myelogenous Leukemia Treatment Market Top ... - The Financial



Chronic Myelogenous Leukemia Treatment Market Top ... 
The Financial
Chronic Myelogenous Leukemia Treatment Market report provides comprehensive analysis for those who are looking for Business expand in various regions, manufacturers, New entrants in the industry, Professional services/solutions providers, Government ...

and more » 


Tasigna (nilotinib; Novartis) Drug Analysis 2018: An Orally ... - Business Wire (press release)



Tasigna (nilotinib; Novartis) Drug Analysis 2018: An Orally ... 
Business Wire (press release)
Tasigna (nilotinib; Novartis) is an orally administered BCR-ABL tyrosine kinase inhibitor. In Philadelphia chromosome-positive chronic myeloid leukemia, the BCR-ABL protein activates a number of cell cycle-controlling proteins and enzymes, speeding up ...

and more » 


Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care - AJMC.com Managed Markets Network



Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care 
AJMC.com Managed Markets Network
A much earlier study by Mahon and some of his colleagues, published in 2001, showed that certain CML cell lines that had developed resistance to specific agents reacquired their sensitivity to the agent when left untreated for a specified period of ...

 


Treating Cancer: Tackling Drug Resistance - Technology Networks



Technology Networks
 
Treating Cancer: Tackling Drug Resistance 
Technology Networks
The drug targets the BCR-ABL fusion gene and is used mainly for cases of chronic myeloid leukemia (CML). When it was first developed, imatinib mesylate was described as the answer to CML, particularly because it produced few side effects. However ...